Menu Close

Articles on pharmaceutical ethics

Displaying all articles

Patients need to know that treatments are recommended based on patient need, not pharma company interests. That’s why it’s important to know how much Big Pharma is paying to health-care providers and organizations. (Shutterstock)

Canadians need to know how much money Big Pharma gives health-care providers, but this information is far too difficult to find

Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
Over 90 per cent of Canadian doctors see pharmaceutical sales representatives. (Shutterstock)

Guidelines governing Canadian doctors’ relationships with pharma companies under review

Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
In this March 18, 2011 photo, Cassidy Hempel waved at hospital staff as she was being treated for a rare disorder. Her mother Chris, left, fought to gain permission for an experimental drug. AP Photo/Marcio Jose Sanchez

Giving patients the ‘right to try’ experimental drugs is a political maneuver, not a lifesaver

Congress has sent a bill to the White House. It gives terminally-ill patients more false hope than chances for a cure.
Thalidomide was used by the pregnant women – the population that turned out to be most vulnerable to its risks. Reuters pictures

Why did thalidomide’s makers ignore warnings about their drug?

Thalidomide’s manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?

Top contributors

More